Evidence map›Paper›PMID 42396206›Full record

ArticleArXiv2026

pVACtools v6: A comprehensive suite for neoantigen prediction, visualization, and therapy design.

My H Hoang, Susanna Kiwala, Megan Richters, Luke Hendrickson, Huiming Xia, Evelyn Schmidt, Christopher A Miller, Kelsy C Cotto, Cheryl F Lichti, Zach Skidmore and 16 more

Abstract readPreprint
In one paragraph

Article in ArXiv, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

My H HoangDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Susanna KiwalaDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Megan RichtersDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Luke HendricksonDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Huiming XiaDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Evelyn SchmidtDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Christopher A MillerDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Kelsy C CottoDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Cheryl F LichtiDepartment of Pathology & Immunology, Washington University School of Medicine, St Louis, MO, USA.
Zach SkidmoreDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Kartik SinghalDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Jennie X YaoDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Jinglun LiDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Mariam KhanfarDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Isabel RischDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Jeffrey WardDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Ramaswamy GovindanDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Gavin DunnDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Tanner M JohannsDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
S Peter GoedegebuureSiteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA.
Todd A FehnigerDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Rachel KarchinDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA.
Robert D SchreiberSiteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA.
William GillandersSiteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA.
Obi L GriffithDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
Malachi GriffithDivision of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
SURGICAL ONCOLOGY TRAINING GRANTT32CA009621 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN, William E. Gillanders · 1988 to 2026
$12.9M
Washington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI HAWKINS, WILLIAM G · 2016 to 2020
$10.9M
Washington University SPORE in Pancreatic CancerP50CA272213 · NCI · WASHINGTON UNIVERSITY · PI David G DeNardo, WILLIAM G HAWKINS · 2023 to 2026
$10.7M
Training Program in Cellular and Molecular BiologyT32GM139774 · NIGMS · WASHINGTON UNIVERSITY · PI HEATHER L TRUE-KROB · 2021 to 2026
$6.7M
Standardized and Genome-Wide Clinical Interpretation of Complex Genotypes for Cancer Precision MedicineU24CA237719 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2019 to 2023
$3.8M
Targeting Neoantigens in Triple Negative Breast CancerR01CA240983 · NCI · WASHINGTON UNIVERSITY · PI GILLANDERS, WILLIAM E., SCHREIBER, ROBERT DAVID · 2019 to 2023
$3.2M
Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung CancerU01CA231844 · NCI · WASHINGTON UNIVERSITY · PI GOVINDAN, RAMASWAMY, GRIFFITH, OBI L. · 2018 to 2022
$3.1M
Beyond Binding: Personalized Multi-omic Neoantigen IdentificationR01CA301054 · NCI · JOHNS HOPKINS UNIVERSITY · PI Malachi Griffith, Rachel Karchin · 2025 to 2026
$1.3M
Informatics tools for identification, prioritization and clinical application of neoantigensU01CA248235 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2020 to 2022
$1.3M
DEVELOPMENT OF INFORMATICS RESOURCES FOR INTERPRETATION OF CLINICALLY ACTIONABLE VARIANTS IN CANCERU01CA209936 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2016 to 2018
$1.0M
NCATS NIH HHS UL1 TR002345NCI NIH HHS P30 CA091842NCI NIH HHS P50 CA196510NCI NIH HHS P50 CA272213NCI NIH HHS R01 CA240983NCI NIH HHS R01 CA301054NCI NIH HHS T32 CA009621NCI NIH HHS U01 CA209936NCI NIH HHS U01 CA231844NCI NIH HHS U01 CA248235NCI NIH HHS U24 CA237719NIGMS NIH HHS T32 GM139774
6 · The paper itself

Abstract

With the rise of checkpoint blockade therapies and neoantigen-based vaccines reaching later-stage trials, there is a growing need for computational tools to identify and prioritize neoantigens. pVACtools, initially introduced in 2016

Identifiers

PMID42396206
PMCPMC13321332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.